| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-06-02 | AstraZeneca (UK) Grunenthal (Germany) | Zurampic® (lesinurad) | gout | licensing | Inflammatory diseases | Licensing agreement |
| 2016-06-02 | Achaogen (USA - CA) Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) (USA) | plazomicin | complicated urinary tract infections (cUTI) | services contract | Infectious diseases | Services contract |
| 2016-06-01 | Txcell (France) Lübeck Institute of Experimental Dermatology (LIED) (Germany) | CAR-Treg-based cellular immunotherapy | bullous pemphigoid (BP) | R&D |
Autoimmune diseases - Dermatological diseases - Rare diseases | R&D agreement |
| 2016-06-01 | ProBioGen (Germany) Merus (The Netherlands) | GlymaxX® Antibody Glyco-Engineering technology | licensing |
Technology - Services - Cancer - Oncology | Licensing agreement | |
| 2016-06-01 | Nektar Therapeutics (USA - CA) Daiichi Sankyo (Japan) | Onzeald™ (etirinotecan pegol) | advanced breast cancer and brain metastases | licensing |
Cancer - Oncology | Licensing agreement |
| 2016-05-31 | Bionor Pharma (Norway) | restructuring |
Infectious diseases | Restructuring | ||
| 2016-05-31 | Neurosearch (Denmark) Saniona (Denmark) | ACR325 and ACR343 | product acquisition |
Neurodegenerative diseases | Product acquisition | |
| 2016-05-31 | DBV Technologies (France) Nestlé Health Science (France) | patch-test tool based on the Viaskin® technology platform | MAG1C, Cow’s Milk Protein Allergy (CMPA) in infants | development commercialisation |
Allergic diseases - Diagnostic - Technology - Services | Development agreement |
| 2016-05-30 | Genmab (Denmark) Janssen Biotech - J&J (USA - NJ) | daratumumab (HuMax®-CD38) | multiple myeloma, other cancer indications such as acute myeloid leukemia | licensing |
Cancer - Oncology | Milestone |
| 2016-05-30 | Valneva (France- Austria) | restructuring |
Infectious diseases | Restructuring | ||
| 2016-05-27 | TG Therapeutics (USA - NY) Jubilant Biosys (India) Checkpoint Therapeutics (USA - NY) | BET inhibitor program | hematological malignancies | development licensing |
Cancer - Oncology | Licensing agreement |
| 2016-05-26 | Oasmia Pharmaceutical (Sweden) | commercialisation |
Cancer - Oncology - Veterinary medicine | Commercialisation agreement | ||
| 2016-05-26 | Alkermes (Ireland) | nomination |
Nomination | |||
| 2016-05-25 | Philips (The Netherlands) Heart Hospital Tampere (Finland) | collaboration |
Cardiovascular diseases | Collaboration agreement | ||
| 2016-05-25 | Thunderbolt, a Vitesse Biologics company (USA - DE) Astellas Pharma (Japan) | BAFF/APRIL dual antagonist program | B cell disorders including systemic lupus erythematosus | product acquisition |
Autoimmune diseases - Cancer - Oncology - Hematological diseases - Immunological diseases | Product acquisition |
| 2016-05-25 | Alder Biopharmaceuticals (USA - WA) | nomination | Inflammatory diseases | Nomination | ||
| 2016-05-24 | Silence Therapeutics (UK) | nomination |
Nomination | |||
| 2016-05-24 | Adaptimmune (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-05-24 | Adaptimmune (UK) | resignation nomination |
Cancer - Oncology | Resignation | ||
| 2016-05-24 | Catalyst Biosciences (USA - CA) CMC Biologics (Denmark) | CB 813d (recombinant factor VIIa) | hemophilia A, hemophilia B | production manufacturing |
Rare diseases - Genetic diseases - Hematological diseases | Production agreement |
